These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20080890)

  • 1. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.
    Nguyen NC; Bhatla D; Osman MM
    J Nucl Med; 2010 Feb; 51(2):330-1; author reply 331. PubMed ID: 20080890
    [No Abstract]   [Full Text] [Related]  

  • 2. 123I-MIBG versus 18F-FDG: which is better, or which can be eliminated?
    Heston TF
    J Nucl Med; 2010 Feb; 51(2):330; author reply 331. PubMed ID: 20080883
    [No Abstract]   [Full Text] [Related]  

  • 3. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.
    Sharp SE; Shulkin BL; Gelfand MJ; Salisbury S; Furman WL
    J Nucl Med; 2009 Aug; 50(8):1237-43. PubMed ID: 19617326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
    Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
    J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET/CT imaging in neuroblastoma.
    Piccardo A; Lopci E; Conte M; Foppiani L; Garaventa A; Cabria M; Villavecchia G; Fanti S; Cistaro A
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):29-39. PubMed ID: 23474633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy.
    Shulkin BL; Hutchinson RJ; Castle VP; Yanik GA; Shapiro B; Sisson JC
    Radiology; 1996 Jun; 199(3):743-50. PubMed ID: 8637999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuroblastoma staging: discrepancies between ¹⁸F-FDG-PET and ¹²³I-MIBG].
    Mena LM; Muros MA; Palacios H; Moreno MJ; Santiago A; Llamas JM
    An Pediatr (Barc); 2010 Dec; 73(6):363-4. PubMed ID: 20817583
    [No Abstract]   [Full Text] [Related]  

  • 8. [Case of 131I-meta-iodobenzylguanidine (MIBG) scintigraphy-negative and 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)-positive pheochromocytoma].
    Jotoku M; Okura T; Nagao T; Enomoto D; Irita J; Miyoshi K; Kurata M; Fukuoka T; Higaki J
    Nihon Jinzo Gakkai Shi; 2009; 51(5):563-8. PubMed ID: 19715165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma.
    Taggart DR; Han MM; Quach A; Groshen S; Ye W; Villablanca JG; Jackson HA; Mari Aparici C; Carlson D; Maris J; Hawkins R; Matthay KK
    J Clin Oncol; 2009 Nov; 27(32):5343-9. PubMed ID: 19805691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative.
    Mc Dowell H; Losty P; Barnes N; Kokai G
    Pediatr Blood Cancer; 2009 Apr; 52(4):552. PubMed ID: 19058210
    [No Abstract]   [Full Text] [Related]  

  • 11. PET hydroxyephedrine imaging of neuroblastoma.
    Shulkin BL; Wieland DM; Baro ME; Ungar DR; Mitchell DS; Dole MG; Rawwas JB; Castle VP; Sisson JC; Hutchinson RJ
    J Nucl Med; 1996 Jan; 37(1):16-21. PubMed ID: 8543986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weak uptake of 123I-MIBG and 18F-FDOPA contrasting with high 18F-FDG uptake in stage I neuroblastoma.
    Wartski M; Jehanno N; Michon J; de Labriolle-Vaylet C; Montravers F
    Clin Nucl Med; 2015 Dec; 40(12):969-70. PubMed ID: 26544903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma.
    Cistaro A; Quartuccio N; Caobelli F; Piccardo A; Paratore R; Coppolino P; Sperandeo A; Arnone G; Ficola U
    Nucl Med Rev Cent East Eur; 2015; 18(2):102-6. PubMed ID: 26315872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
    Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
    J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brown fat imaging with (18)F-6-fluorodopamine PET/CT, (18)F-FDG PET/CT, and (123)I-MIBG SPECT: a study of patients being evaluated for pheochromocytoma.
    Hadi M; Chen CC; Whatley M; Pacak K; Carrasquillo JA
    J Nucl Med; 2007 Jul; 48(7):1077-83. PubMed ID: 17574980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
    Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
    J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative.
    Colavolpe C; Guedj E; Cammilleri S; Taïeb D; Mundler O; Coze C
    Pediatr Blood Cancer; 2008 Dec; 51(6):828-31. PubMed ID: 18680162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma.
    Melzer HI; Coppenrath E; Schmid I; Albert MH; von Schweinitz D; Tudball C; Bartenstein P; Pfluger T
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1648-58. PubMed ID: 21617976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma.
    Ilias I; Chen CC; Carrasquillo JA; Whatley M; Ling A; Lazúrová I; Adams KT; Perera S; Pacak K
    J Nucl Med; 2008 Oct; 49(10):1613-9. PubMed ID: 18794260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benign differentiation of treated neuroblastoma as a cause of false positive by
    Garcia JR; Bassa P; Soler M; Jaramillo A; Ortiz S; Riera E
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(6):389-390. PubMed ID: 31000447
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.